Ipsen teams up with Syntaxin to create new botulinum toxin therapeutics
Executive Summary
Ipsen and Syntaxin Ltd. (neurology and metabolic medicines) have teamed up to develop new botulinum toxin therapeutics. Botulinum toxin is used to treat a variety of conditions, including blepharospasm, strabismus, hemifacial spasm, wrinkles, excessive sweating, cervical dystonia, and chronic migraine.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice